Allarity Therapeutics, Inc. ALLR 深 沪
已收盘 10-30 16:00:00 美东时间
0.8704
-0.020
-2.20%
华盛通- 最 高0.9046
- 今 开0.89
- 成交量 17.95万股
- 最 低 0.85
- 昨 收 0.89
- 总市值 1384.87万
- 52周最高 1.8395
- 市盈率 静 --
- 换手率 1.13%
- 52周最低 0.7687
- 委 比 94.89%
- 总股本 1591.07万
- 历史最高 15288000.00
- 量 比 1.49
- 振 幅 6.13%
- 历史最低 0.6138
- 每 手 1
- 风险率 0.20%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Allarity Therapeutics Receives First Contract For Its Development, Validation And Related Laboratory Services From Undisclosed European Biotech Firm
Allarity Therapeutics, Inc. ("Allarity" or the "Company") (NASDAQ:ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib (2X-121)—a differentiated, dual PARP and WNT pathway inhibitor— today announced its first revenue-generating contract under its newly establishe...
10-30 19:46
Allarity Therapeutics Highlights DRP Technology, Patent And Lab Advances To Support Stenoparib Development And Partnerships
Allarity Therapeutics, Inc. ("Allarity" or the "Company") (NASDAQ:ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib (2X-121)—a differentiated, dual PARP and WNT pathway inhibitor— today provided an update on recent advances in its proprietary Drug Response Pre...
09-30 21:11
美股大行评级 | 矿业股获齐声唱多！金田、纽曼矿业等目标价均获上调；携程遭看淡至60美元，较现价仍溢价5成
今日重点评级关注：Ascendiant Capital：维持Allarity Therapeutics"买入"评级，目标价从10.25美元升至11美元；Needham：上调Rocket Pharmaceuticals"买入"评级，目标价9美元
09-17 16:16
Rapport Therapeutics To Rally Around 76%? Here Are 10 Top Analyst Forecasts For Wednesday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. BTIG raised the price target for Rapport Therapeutics Inc (NASDAQ:RAPP) from $65 to $75. BTIG analyst Kambiz Y...
09-16 21:10
Ascendiant Capital Maintains Buy on Allarity Therapeutics, Raises Price Target to $11
Ascendiant Capital analyst Edward Woo maintains Allarity Therapeutics (NASDAQ:ALLR) with a Buy and raises the price target from $10.25 to $11.
09-16 17:36
Allarity Therapeutics Q2 EPS $(0.21) Beats $(0.25) Estimate
Allarity Therapeutics (NASDAQ:ALLR) reported quarterly losses of $(0.21) per share which beat the analyst consensus estimate of $(0.25) by 16 percent. This is a 40 percent decrease over losses of $(0.15) per share from the same period last year.
08-14 20:17
美股大行评级 | 存储再获看多！美光、闪迪、西部数据获机构上调目标价；次新股Cerebras、Blackstone、EagleRock获多家机构首予买入平均
今日重点评级关注：Ascendiant Capital：维持IGC Pharma"买入"评级，目标价从5.25美元升至5.5美元；Ascendiant Capital：维持Lucid Diagnostics"买入"评级，目标价从9美元升至9.25美元
06-09 11:33
Ascendiant Capital Maintains Buy on Allarity Therapeutics, Raises Price Target to $10.25
Ascendiant Capital analyst Edward Woo maintains Allarity Therapeutics (NASDAQ:ALLR) with a Buy and raises the price target from $9.75 to $10.25.
06-08 17:52
Allarity Therapeutics Q1 EPS $(0.17) Beats $(0.22) Estimate, Sales $25.000K
Allarity Therapeutics (NASDAQ:ALLR) reported quarterly losses of $(0.17) per share which beat the analyst consensus estimate of $(0.22) by 22.73 percent. This is a 32 percent increase over losses of $(0.25) per share
05-16 04:31
Allarity Therapeutics shares are trading higher after the company announced that its active pharmaceutical ingredient manufacturing campaign for stenoparib is progressing in line with the planned timeline for completion, no later than Q3 of 2026, at its world-class contract development and manufacturing organization.
Allarity Therapeutics shares are trading higher after the company announced tha...
05-06 00:16
